General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-07 | 2024-03 | -0.2 | N/A | N/A | N/A |
2024-03-11 | 2023-12 | -0.23 | -0.2 | 0.03 | 13.04% |
2023-11-08 | 2023-09 | -0.22 | -0.21 | 0.01 | 4.55% |
2023-08-03 | 2023-06 | -0.17 | -0.22 | -0.05 | -29.41% |
2023-05-02 | 2023-03 | -0.17 | -0.17 | N/A | N/A |
2023-03-02 | 2022-12 | -0.14 | -0.16 | -0.02 | -14.29% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-05-30 | Citigroup | Upgrade | Buy | Buy |
2023-05-29 | Needham | Upgrade | Hold | |
2023-03-06 | Jefferies | Upgrade | Hold | |
2022-11-21 | Citigroup | Upgrade | Buy | Buy |
2022-08-11 | Piper Sandler | Upgrade | Overweight | |
2022-06-30 | Citigroup | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-02-27 | ALEXANDER KRISTEN | Officer | 47.80K | Conversion of Exercise of derivative security |
2023-11-12 | AMOUYAL PHILIPPE J | Director | 240.33K | Purchase |
2024-03-12 | ARTAL INTERNATIONAL S.C.A. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
2024-02-27 | COATS LONNEL | Chief Executive Officer | 1.10M | Conversion of Exercise of derivative security |
2024-02-27 | CRUM BRIAN T | General Counsel | 177.50K | Conversion of Exercise of derivative security |
2024-02-27 | GRANOWITZ CRAIG B. M.D., PH.D. | Officer | 47.63K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Artal Group S.A. | 117.55M | 269.20M | 48.00% |
2023-06-29 | BVF Inc. | 20.00M | 45.79M | 8.16% |
2023-06-29 | FMR, LLC | 8.51M | 19.49M | 3.47% |
2023-06-29 | Vanguard Group Inc | 6.46M | 14.79M | 2.64% |
2023-06-29 | Blackrock Inc. | 6.38M | 14.61M | 2.60% |
2023-06-29 | JP Morgan Chase & Company | 2.93M | 6.71M | 1.20% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.70M | 8.48M | 1.51% |
2023-08-30 | Fidelity Growth Company Fund | 2.53M | 4.35M | 1.03% |
2023-08-30 | iShares Russell 2000 ETF | 2.15M | 3.69M | 0.88% |
2023-06-29 | JP Morgan Small Cap Value Fund | 1.43M | 3.27M | 0.58% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.42M | 3.25M | 0.58% |
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 1.09M | 1.87M | 0.44% |
Split | Date |
---|---|
1 : 7 | 2015-05-21 |
I think this company is trying to run on their own but can’t. I just hope they don’t eventually surrender to a weak takeover bid. Doesn’t make sense with an FDA approval we are still with a 1 handle. What is the market trying to tell me !
You’re missing a great party LEX. Every single stock on the board is trading higher. Sad.
Nothing logical about this SP, if you are holding some of the 20m short shares, Zacks upgrades this to a buy, there is a 3 hour investor day scheduled in a couple days and the share price is at this level, would you not be running to buy back here? Why risk a serious run up? Logically you would think shorts would cover today and Friday, SP would jump Monday and then short again, maybe. What drove this to mid 3s a few months ago? Why with a pipeline like this is the SP under $2?
Nothing logical right now .
Expecting a sizable bump by Investor Day.
https://finance.yahoo.com/news/know-lexicon-lxrx-rating-upgrade-160009709.html
What about earnings. Any news
These guys are probably among the best researchers for new drugs I agree but they have no clue how to run a business and the market is all about running business. I’m out as well. Good luck to all.
The more this company is trying to come up with good news the more it triggers selling. Just like a house who’s been in the market for too long, this stock looks Burned. Brutal
I see most all shorts exiting between now and April investor day. Lexi has serious legs and could easily double from here. I’m not as smart as the shorts but see what’s on the horizon and the next 6 mo look extremely promising. 4-10 price targets likely to be taken out and go higher.
The current consensus EPS estimate is -$0.24 on $1 million in revenues for the coming quarter and -$0.86 on $26.87 million in revenues for the current fiscal year.
Only 1M? Seems low based off Q4, considering hospital formularies 6 month waiting period ended and several big plans have picked up Impefa starting Jan 1 or around there.
I expect revisions to estimate to at least double.
Am I off base?
What is going on ? Are these guys afraid to post their earnings or what !